WELCOME TO
ExpreS2ion Biotech
INVESTOR SITE
Upcoming events
- 25/02/21
Year-end report, 2020
- 19/05/21
Interim report, Q1 2021
- 26/05/21
Annual General Meeting, 2021
- 19/08/21
Half-year report, 2021
- 18/11/21
Interim report, Q3 2021
- 24/02/22
Year-end report, 2022
Latest press releases
ExpreS2ion Announces 2020 Fourth Quarter and Full-Year Results
This is a regulatory release
Hørsholm, Denmark, February 25, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its full-year financial results for 2020 and the fourth quarter of 2020. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.
ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models
This is a regulatory release
Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the…